RFK Jr. promotes peptides. Now the FDA weighs easing limits on the unproven chemicals The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions The FDA's Current Position on Peptides Explained Holt Law The Emerging Risk of Peptides in Supplements LegitScript Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law Gray Market Peptides: So Much Hype, So Little Data